Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies

Nature Medicine

Volumn 21, Issue 11, 2015, Pages 1332-1336

  Bhiman, Jinal N ^a,b   Anthony, Colin ^c   Doria Rose, Nicole A ^d   Karimanzira, Owen ^a   Schramm, Chaim A ^e   Khoza, Thandeka ^a   Kitchin, Dale ^a   Botha, Gordon ^c   Gorman, Jason ^d   Garrett, Nigel J ^f   Karim, Salim S Abdool ^f   Shapiro, Lawrence ^d,e   Williamson, Carolyn ^c,f,g   Kwong, Peter D ^d   Mascola, John R ^d   Morris, Lynn ^a,b,f   Moore, Penny L ^a,b,f  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

^g NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BROADLY NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; EPITOPE; GLYCOPROTEIN GP 120; HIV ENVELOPE PROTEIN GP120 (135-148); HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PEPTIDE FRAGMENT; VIRUS RNA;

ARTICLE; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; VIRUS MUTATION; ANTIGENIC VARIATION; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; SEQUENCE ANALYSIS; SERODIAGNOSIS; SUPERINFECTION;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIGENIC VARIATION; EPITOPES; FEMALE; GENETIC VARIATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; SUPERINFECTION;

EID: 84946576244     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3963     Document Type: Article

References (41)

1. Gray, E.S. et al. HIV-1 neutralization breadth develops incrementally over 4 years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85, 4828-4840 (2011).
2. Hraber, P. et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28, 163-169 (2014).
3. Piantadosi, A. et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 83, 10269-10274 (2009).
4. Sather, D.N. et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757-769 (2009).
5. Euler, Z. et al. Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J. Virol. 86, 2045-2055 (2012).
6. Walker, L.M. et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6, e1001028 (2010).
7. Doria-Rose, N.A. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55-62 (2014).
8. Liao, H.X. et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469-476 (2013).
9. Mascola, J.R., & Haynes, B.F. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254, 225-244 (2013).
10. Gao, F. et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 158, 481-491 (2014).
11. Wibmer, C.K. et al. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 9, e1003738 (2013).
12. Moore, P.L. et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 18, 1688-1692 (2012).
13. Moore, P.L. et al. Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J. Virol. 87, 4882-4894 (2013).
14. Doria-Rose, N.A. et al. A new member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J. Virol. (in the press).
15. Klein, F. et al. Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199-1204 (2013).
16. Kwong, P.D., Mascola, J.R., & Nabel, G.J. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat. Rev. Immunol. 13, 693-701 (2013).
17. Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. USA 111, 17624-17629 (2014).
18. Walker, L.M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
19. Scheid, J.F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636-640 (2009).
20. Mouquet, H. et al. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS ONE 6, e24078 (2011).
21. Pappas, L. et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 516, 418-422 (2014).
22. Walker, L.M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
23. Briney, B.S., Willis, J.R., & Crowe, J.E. Jr. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS ONE 7, e36750 (2012).
24. Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374-1377 (2003).
25. Jardine, J. et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340, 711-716 (2013).
26. McGuire, A.T. et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 210, 655-663 (2013).
27. van Loggerenberg, F. et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS ONE 3, e1954 (2008).
28. Jabara, C.B., Jones, C.D., Roach, J., Anderson, J.A., & Swanstrom, R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc. Natl. Acad. Sci. USA 108, 20166-20171 (2011).
29. Goecks, J., Nekrutenko, A., Taylor, J., & Galaxy, T. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol. 11, R86 (2010).
30. Blankenberg, D. et al. Galaxy: a web-based genome analysis tool for experimentalists. Curr. Protoc. Mol. Biol. 89, 19.10.1-19.10.21 (2010).
31. Giardine, B. et al. Galaxy: a platform for interactive large-scale genome analysis. Genome Res. 15, 1451-1455 (2005).
32. Blankenberg, D. et al. Manipulation of FASTQ data with Galaxy. Bioinformatics 26, 1783-1785 (2010).
33. Katoh, K., & Standley, D.M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772-780 (2013).
34. Edgar, R.C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792-1797 (2004).
35. Wright, I.A., & Travers, S.A. RAMICS: trainable, high-speed and biologically relevant alignment of high-Dhroughput sequencing reads to coding DNA. Nucleic Acids Res. 42, e106 (2014).
36. Hunter, J.D. Matplotlib: A 2D graphics environment. Comput. Sci. Eng. 9, 90-95 (2007).
37. Salazar-Gonzalez, J.F. et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 82, 3952-3970 (2008).
38. Gao, F. et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J. Virol. 70, 1651-1667 (1996).
39. Kraus, M.H. et al. A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays. Virology 397, 346-357 (2010).
40. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
41. Hall, T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl. Acids. Symp. Ser. 41, 95-98 (1999).